Made in Italy: ‘beIT’ campaign to promote Italy at 360° kicks off

Luigi Di Maio

ROME, Nov. 30, 2021 (GLOBE NEWSWIRE) — (LaPresse) – An extraordinary communication campaign to promote Made in Italy, entitled ‘Italy is simply extraordinary: beIT’, has been successfully launched. The campaign, launched by the Italian Ministry of Foreign Affairs and International Cooperation in collaboration with the Italian Trade Agency (ICE), will have a global dimension with a particular focus on 26 countries.

“’beIT’ is the first nation-branding campaign ever created for Italy,” explained Foreign Minister Luigi Di Maio, “with a new approach that stands out from what has been done so far; the project we have launched is complex and ambitious, as it aims to tell the international public about Italy today, at 360°”. The campaign has two main objectives: to tell the international public about Italy, its values and talents, its skills and extraordinary potential in an original and innovative way; and to support the internationalisation of Italy’s supply chains, expanding and diversifying the foreign markets of reference for Italian SMEs.

The ‘beIT’ campaign “conveys a new image of Italy”: “the image associated with stereotypes is well known and established, but the image of a cutting-edge Italy, at the forefront of technology and innovation, is not as readily acknowledged. We are leaders in many sectors and markets that are extremely innovative, yet these aspects are not known. The idea behind this campaign is to move in this direction and tell the story of a new Italy”, explained Franco Pomilio, CEO of the communication agency Pomilio Blumm, which won the call for tenders to design the campaign.

“’beIT’, which was designed with the idea of being ‘disruptive’, of creating a narrative of the Italian System, a narrative from the bottom up where content is partly produced by us and partly by the network of the Ministry of Foreign Affairs and the Agency for Development Cooperation: it is a large container that aims to become a platform to promote what it means to be Italian”, Pomilio stressed.

The campaign was launched on 29 November 2021 and will run until August 2022, divided into two phases. The first phase will run from November 2021 to March 2022 and will focus on the ‘values’ that identify Italy: creativity, passion, tradition, style, innovation, and diversity. The second phase will see the implementation of targeted campaigns, from March to August 2022, aimed at promoting Made in Italy production chains.

The communication campaign will focus on the digital channels and will involve the creation of a new visual and linguistic identity for all activities promoting Italy around the world, as well as dedicated platforms and landing pages, social profiles, and original content. The campaign will also have a ‘green’ slant, in collaboration with the Italian company Treedom.

For more information:
LaPresse SpA Communication and Press Office Director
Barbara Sanicola –
+39 02 26305578 M +39 333 3905243

A photo accompanying this announcement is available at

Bitdeer Group Contributes to Local Communities in Wyoming and Texas

Bitdeer Group gives back to the communities of Wyoming and Rockdale, Texas

Bitdeer Group Contributes to Local Communities in Wyoming and Texas

Bitdeer Group Contributes to Local Communities in Wyoming and Texas

SINGAPORE, Nov. 30, 2021 (GLOBE NEWSWIRE) — Bitdeer Group provides digital asset mining services to individual and institutional clients around the world, and has set up branches in North America, Europe, and other regions. It is committed to convenience, user satisfaction, and reliability, in addition to giving back to the local communities where it operates.

Bitdeer Group views community engagement as a top priority. These opportunities give Bitdeer a platform to actively solve problems in the community while building a better future for its employees as well as their friends and families. Bitdeer Group is enthusiastic to contribute in any way it can, from financial donations to facilitating educational programs and expanding career opportunities. Most recently, Bitdeer’s community contributions include sponsoring the University of Wyoming WyoHackathon and making a critical donation to the Rockdale Volunteer Fire Department.

The University of Wyoming WyoHackathon: Using Blockchain to Reimagine Economic Revitalization

On Sept. 15, 2021, Bitdeer Group sponsored the University of Wyoming’s annual WyoHackathon. Bitdeer Group’s contribution allowed University of Wyoming students to engage with crypto industry experts as well as leaders across the spectrum of emerging blockchain use cases.

Bitdeer Group also participated in a workshop for the university’s Mining Club. Bitdeer Group brought an S19 mining machine and explained the hardware’s computing mechanisms as well as demonstrated industry-standard repair techniques.

Bitdeer Group wanted to be involved with the WyoHackathon to further develop Wyoming’s ambitions to become the epicenter of blockchain tech in the United States. Joining forces with the University of Wyoming dually cultivates talent for the future of the industry.

Donation and Involvement in Rockdale, Texas

One of Bitdeer Group’s largest mining datacenter is in Rockdale, Texas. Like many rural parts of the U.S., Rockdale does not have a government-funded fire department. On Oct. 27, 2021, Bitdeer Group donated to the Rockdale Volunteer Fire Department. This donation enabled these brave first responders, who also have full-time ”day” jobs, to purchase emergency ventilator equipment.

Bitdeer Group is planning a concerted community engagement strategy for 2022, prioritizing initiatives that facilitate sustained economic impact which include social responsibilities from tax contribution to local government, to increased job opportunities and economic returns for the local community.

About Bitdeer Group

Bitdeer Group is the world’s leading digital asset mining service provider. It was founded by Jihan Wu, Co-Founder of Bitmain and Matrixport, with venture investment from Sequoia Capital, IDG, and other well-known investment groups in the blockchain space. Headquartered in Singapore, Bitdeer Group currently operates in the United States and Europe. The Group has three business lines — Bitdeer, Mining Datacenter, and Minerplus — demonstrating the dedication and expertise to become the world’s most reliable digital asset mining service provider.

For more information, please get in touch with Bitdeer Group:



Media Contact:


Business Cooperation:

Mining Datacenter Partnership:

*Information provided in this article is for general information and reference only and does not constitute nor is intended to be construed as any advertisement, professional advice, offer, solicitation, or recommendation to deal in any product. No guarantee, representation, warranty or undertaking, express or implied, is made as to the fairness, accuracy, timeliness, completeness or correctness of any information, or the future returns, performance or outcome of any product. Bitdeer expressly excludes any and all liability (to the extent permitted by applicable law) in respect of the information provided in this article, and in no event shall Bitdeer be liable to any person for any losses incurred or damages suffered as a result of any reliance on any information in this article.

Related Images

Image 1: Bitdeer Group Contributes to Local Communities in Wyoming and Texas

This content was issued through the press release distribution service at


Degreed named as a Core Challenger in the 2021 Fosway 9-Grid™ for Talent & People Success

The new position reflects Degreed’s continued investment in its product features, market potential, and leadership strength

PLEASANTON, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) — Degreed, the workforce upskilling platform, has been named as a Core Challenger in the Fosway 2021 9-Grid™ for Talent & People Success. The new positioning, up from Potential Challenger in 2020, reflects the strength and differentiation of the Degreed offering for Talent and People Success leaders, namely the introduction of its experiential learning and opportunities features.

Organizations have increasingly realized the importance of retaining their talent and readying them for future needs. In response to this, Degreed developed its opportunity marketplace product, bringing experiential learning and internal mobility to learning to help people apply and stretch new skills through temporary projects and roles, mentoring and volunteering, and stretch assignments.

Participants in the Fosway 9-Grid™ for Talent & People Success are rated based on their solution’s potential, performance and customer advocacy, market presence, total cost of ownership, and future trajectory (in relation to market trends).

David Wilson, CEO, Fosway Group, said: “Skills have become a very immediate as well as strategic challenge for organisations as they adapt to the post-pandemic working environment. Degreed has progressed its position in the 2021 Fosway 9-Grid™ for Talent & People Success by innovating its products to enable customers to accelerate their skills development and encourage talent mobility by growing talent from within.”

Todd Tauber, SVP Strategy at Degreed, said: “Degreed’s position as a Core Challenger validates the continued investment we are making in our features to ensure every worker can remain employable amidst uncertainty. Degreed users benefit from learning in the flow of work, opportunities to stretch their skills, and a consistent way to track all forms of development. We are grateful that Fosway’s rigorous assessment of Degreed’s performance, potential, and presence, shows the power of our strategy and differentiation.”

To discover more about Degreed, visit its website or learn more about the Fosway 9-Grid™ here.

Editor’s notes

About Degreed

Degreed is the workforce upskilling platform chosen by one in three Fortune 50 companies. We connect all your learning and internal mobility opportunities to intelligence on the skills your business needs next. And we do it all in one simple, fluid, skill-building experience that’s powered by your people’s expertise and interests. So you can transform your workforce from within. Founded in 2012, Degreed is headquartered in Pleasanton, California, with additional offices in Salt Lake City, New York, London, Amsterdam, and Brisbane.

Learn more about Degreed: Website | YouTube | LinkedIn | Twitter

About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR and learning analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 customer organisations, including BP, HSBC, PwC, RBS, Sanofi, Shell and Vodafone.

Visit the Fosway website at for more information on Fosway Group’s research and services.

Sarah Danzl
Head of Global Communications, Degreed

CNH Industrial completes the acquisition of Raven Industries

London, November 30, 2021

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announced that it has completed its acquisition of Raven Industries, Inc., a U.S.-based leader in precision agriculture technology. The acquisition builds upon a long partnership and is an important milestone in CNH Industrial’s digital transformation.

“Raven is a true pioneer in the precision agriculture space, and their technology is a perfect strategic fit that will differentiate us from our peers and significantly improve our competitive position,” said Scott Wine, Chief Executive Officer, CNH Industrial. “This acquisition will add strong innovation capabilities to accelerate our precision and digital strategy. I would like to commend both the Raven and CNH Industrial teams who are collaborating closely on a seamless transition to make this truly transformative deal progress smoothly.”

CNH Industrial is laser focused on delivering immediate value for its brands’ dealer partners and their customers, the world’s farmers. The first in-house products featuring fully integrated Raven precision agriculture systems will become available in 2022.

Headquartered in Sioux Falls, South Dakota, Raven was founded over 65 years ago and has created a leadership position in precision agriculture, high performance specialty films, and aerospace and defense solutions.

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website:

Forward-looking statements
All statements other than statements of historical fact contained in this press release including statements regarding our future responses to and effects of the COVID-19 pandemic; competitive strengths; business strategy; future financial position or operating results; budgets; projections with respect to revenue, income, earnings (or loss) per share, capital expenditures, dividends, liquidity, capital structure or other financial items; costs; and plans and objectives of management regarding operations and products, are forward-looking statements. These statements may include terminology such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “outlook”, “continue”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “prospects”, “plan”, or similar terminology. Forward-looking statements, including those related to the COVID- 19 pandemic, are not guarantees of future performance. Rather, they are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are outside our control and are difficult to predict. If any of these risks and uncertainties materialize (or they occur with a degree of severity that the Company is unable to predict) or other assumptions underlying any of the forward-looking statements prove to be incorrect, including any assumptions regarding strategic plans, the actual results or developments may differ materially from any future results or developments expressed or implied by the forward-looking statements. Factors, risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: the unknown duration and economic, operational and financial impacts of the global COVID-19 pandemic and the actions taken or contemplated by governmental authorities or others in connection with the pandemic on our business, our employees, customers and suppliers, including supply chain disruptions caused by mandated shutdowns and the adverse impact on customers, borrowers and other third parties to fulfill their obligations to us; disruption caused by business responses to COVID-19, including remote working arrangements, which may create increased vulnerability to cybersecurity or data privacy incidents; our ability to execute business continuity plans as a result of COVID-19; the many interrelated factors that affect consumer confidence and worldwide demand for capital goods and capital goods-related products, including demand uncertainty caused by COVID-19; general economic conditions in each of our markets, including the significant economic uncertainty and volatility caused by COVID-19; travel bans, border closures, other free movement restrictions, and the introduction of social distancing measures in our facilities may affect in the future our ability to operate as well as the ability of our suppliers and distributors to operate; changes in government policies regarding banking, monetary and fiscal policy; legislation, particularly pertaining to capital goods-related issues such as agriculture, the environment, debt relief and subsidy program policies, trade and commerce and infrastructure development; government policies on international trade and investment, including sanctions, import quotas, capital controls and tariffs; volatility in international trade caused by the imposition of tariffs, sanctions, embargoes, and trade wars; actions of competitors in the various industries in which we compete; development and use of new technologies and technological difficulties; the interpretation of, or adoption of new, compliance requirements with respect to engine emissions, safety or other aspects of our products; production difficulties, including capacity and supply constraints and excess inventory levels; labor relations; interest rates and currency exchange rates; inflation and deflation; energy prices; prices for agricultural commodities; housing starts and other construction activity; our ability to obtain financing or to refinance existing debt; price pressure on new and used vehicles; the resolution of pending litigation and investigations on a wide range of topics, including dealer and supplier litigation, follow-on private litigation in various jurisdictions after the settlement of the EU antitrust investigation announced on July 19, 2016, intellectual property rights disputes, product warranty and defective product claims, and emissions and/or fuel economy regulatory and contractual issues; our pension plans and other post-employment obligations; further developments of the COVID-19 pandemic on our operations, supply chains, distribution network, and level of demand for our products, as well as negative evolutions of the economic and financial conditions at global and regional levels; political and civil unrest; volatility and deterioration of capital and financial markets, including possible effects of “Brexit”, other pandemics, terrorist attacks in Europe and elsewhere; our ability to realize the anticipated benefits from our business initiatives as part of our strategic plan; the impact of significant or unanticipated material extraordinary transactions or any business combinations and other similar transaction on our businesses; our failure to realize, or a delay in realizing, all of the anticipated benefits of our acquisitions, joint ventures, strategic alliances or divestitures; expected benefits and costs of the proposed spin-off of the Company’s On-Highway business; the expected timing of completion of the spin-off transaction; the ability of the Company to complete the spin-off transaction considering the various conditions to the completion of the spin-off transaction (some of which are outside the Company’s control); business disruption during the pendency of or following the spin-off transaction, diversion of management time on the spin-off transaction-related issues, and other similar risks and uncertainties, and our success in managing the risks involved in the foregoing. Further information concerning factors, risks, and uncertainties that could materially affect the Company’s financial results is included in our annual report on Form 20-F for the year ended December 31, 2020, prepared in accordance with U.S. GAAP and in the Company’s EU Annual Report at December 31, 2020, prepared in accordance with EU-IFRS. Investors are expressly invited to refer to and consider the information on risks, factors, and uncertainties incorporated in the above-mentioned documents, in addition to the information presented here. Forward-looking statements speak only as of the date on which such statements are made, and we undertake no obligation to update or revise publicly our forward-looking statements, whether as a result of new developments or otherwise.

Sign up for corporate news alerts from the CNH Industrial Newsroom:


Corporate Communications

Investor Relations


nCino’s Commercial Banking Solution Ranked “Best-in-Class” by Aite Group for Third Consecutive Time

Customer feedback and product innovation drive nCino as a top technology vendor in the 2021 Impact Matrix

WILMINGTON, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, is proud to be named a Best-In-Class vendor by Aite Group for its Commercial Banking Solution. The only technology vendor to ever achieve the recognition for the third consecutive time, nCino received the highest classification in the Aite Matrix: Commercial Loan Origination Automation report, after scoring top marks in each of the four categories: vendor stability, client strength, client service and product features.

“We are incredibly proud that Aite Group continues to recognize nCino as a leader in commercial loan origination,” said Josh Marcy, EVP of Product Management at nCino. “Our customers who provide feedback and help us continually innovate our product to meet the evolving needs of the market, are the catalyst to how nCino has received this award each year since it was created. Our goal from the start has been to provide an experience for our customers driven by simplicity, efficiency and speed. This acknowledgment from a respected global analyst firm showcases the robustness of the nCino platform and the strength of our partnerships with financial institutions globally.”

The analyst group determined nCino’s Bank Operating System® to be best-in-class based on multiple factors, including:

  • nCino’s cloud-based, single platform solution that stretches across onboarding, deposits and loan origination;
  • nCino’s commitment to innovation and intelligence with the expansion of nCino IQ (nIQ) functionality including intelligent automation with Automated Spreading and rate optimization analysis with the introduction of Commercial Pricing and Profitability; and,
  • The amount of total revenue that nCino invests in research and development to fuel product innovation.

Commenting on nCino’s performance, David O’Connell, Strategic Advisor at Aite-Novarica Group, said, “In the area of Product Features, nCino led because of both its capability breadth and clients’ favorable takes on this vendors ability to assist with digitalization, consult on API strategies, and listen to client requests.” O’Connell went on to add, “Also boosting nCino’s score was its large and diverse customer base.”

As Aite’s report shows, financial institutions around the globe are growing because nCino’s Commercial Banking Solution drives intelligent automation into every corner of the financial institution, enabling the Intelligent Enterprise for the Commercial Bank. Through a single platform, institutions have the power to manage all aspects of the commercial banking process from onboarding to account opening, to loan origination and approval. The results speak for themselves, as the financial services industry transforms to serve a rapidly changing world.

Customer Testimonials

“We partnered with nCino to implement their Commercial Banking Solution and we know the impact nCino will have on connecting disjointed systems, creating continuity across lines of business and supporting the customer journey through any channel. We’re excited about our continued collaboration and partnership with nCino and look forward to developing a plan to integrate more features of the nCino platform in the future.” – WestStar Bank’s New Mexico Market President and Executive Co-Sponsor of nCino, Raymond Baer

“Our relationship-led model means our bankers are focused on spending quality time with our customers to deeply understand their business. However, their time is finite, and so the systems that support them need to take administration off their plate, support communications and generate fast decisions for customers. nCino’s Commercial Banking Solution allows our bankers to continue to support the customer’s experience while also freeing them up to do what they do best – spending quality time with our customers.” – Judo Bank’s Chief Operating Officer, Lisa Frazier

About nCino
nCino (NASDAQ: NCNO) is the worldwide leader in cloud banking. The nCino Bank Operating System® empowers financial institutions with scalable technology to help them achieve revenue growth, greater efficiency, cost savings and regulatory compliance. In a digital-first world, nCino’s single digital platform enhances the employee and client experience to enable financial institutions to more effectively onboard new clients, make loans and manage the entire loan life cycle, and open deposit and other accounts across lines of business and channels. Transforming how financial institutions operate through innovation, reputation and speed, nCino works with more than 1,200 financial institutions globally, whose assets range in size from $30 million to more than $2 trillion. For more information, visit:

Sutton Resler, nCino
+1 571.236.4966

Ryan Kelly
+1 732.770.5942

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally include actions, events, results, strategies and expectations and are often identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Any forward-looking statements contained in this press release are based upon nCino’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent nCino’s expectations as of the date of this press release. Subsequent events may cause these expectations to change and, except as may be required by law, nCino does not undertake any obligation to update or revise these forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially including, among others, risks and uncertainties relating to the market adoption of our solution and privacy and data security matters. Additional risks and uncertainties that could affect nCino’s business and financial results are included in reports filed by nCino with the U.S. Securities and Exchange Commission (available on our web site at or the SEC’s web site at Further information on potential risks that could affect actual results will be included in other filings nCino makes with the SEC from time to time.

Eagle Eye Networks Forecasts Key Video Surveillance Trends for 2022

Businesses are turning to video surveillance to help them adapt and thrive amidst sustained disruptions and changes in the business environment

2022 Trends in Video Surveillance Report Released Today

The 2022 Trends in Video Surveillance report released today is a forecast for business leaders and owners who want to understand the physical security landscape and plan for success in 2022. The report is produced annually by Eagle Eye Networks.

AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) — Eagle Eye Networks, the global leader in cloud video surveillance, today released the 2022 edition of its annual Trends in Video Surveillance ebook, a forecast for business leaders and owners who want to understand the physical security landscape and plan for success in 2022.

“Almost two years into the global pandemic, businesses have experienced sustained disruptions in the supply chain, labor shortage challenges, and vast changes in workplace routines,” said Dean Drako, Eagle Eye Networks CEO. “Business owners’ reliance on video surveillance is increasing because the security and operational insights provided by video surveillance are helping them adapt to the new business environment. Concurrently, the emergence of artificial intelligence (AI) combined with cloud video surveillance promises better, faster, and more accurate analytics for security and business optimization. We expect businesses to rely even more on cloud-based AI analytics to help them thrive in 2022.”

To learn what the following five trends mean for your business, and more insights, download the free 2022 Trends in Video Surveillance ebook here.

Video Surveillance Trends for 2022:

  1. Businesses want the flexibility to add customized analytics to their video surveillance systems.
  2. Video surveillance will help businesses impacted by the labor shortage do more with less.
  3. More customers are understanding the business intelligence value of video surveillance.
  4. Pandemic trends around remote work and home and curbside delivery are here to stay.
  5. Interoperability is key to data management and security.

Eagle Eye Networks is the global leader in cloud video surveillance, delivering cyber-secure cloud-based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. The Eagle Eye Cloud VMS (video management system) is the only platform robust and flexible enough to power the future of video surveillance and intelligence. Eagle Eye is based in Austin, Texas with offices in Amsterdam, Bangalore, and Tokyo. Learn more at

Martha Entwistle

A photo accompanying this announcement is available at

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

4th approved indication for toripalimab

SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supplemental New Drug Application (sNDA) for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma (the “NPC”). This is the fourth approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. In April 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

The sNDA is based on the JUPITER-02 study (NCT03581786), which is a randomized, double-blind, placebo-controlled and international multi-center Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The results of the study showed that when compared with the standard first-line treatment of gemcitabine/cisplatin, toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic NPC has better progression-free survival, higher objective response rate, longer duration of response and survival benefits regardless of PD-L1 expression status with a manageable safety profile. This study is the world’s largest Phase III clinical study for a checkpoint inhibitor in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC. The study results of JUPITER-02 were presented in the form of a Late-breaking Abstract (LBA) at the plenary session at the annual meeting of the American Society of Clinical Oncology (ASCO 2021) and were published as the cover article of the September 2021 issue of Nature Medicine.

“As the world’s first immuno-oncology (I-O) drug approved for the treatment of nasopharyngeal cancer (NPC), we continue to explore the potential of toripalimab in different settings within NPC and across other cancer types, with the support of patients, investigators and our research team participating in clinical trials. We have now received approval for a new indication for toripalimab with chemotherapy for the first-line treatment of NPC, which provides better treatment outcomes for more patients with advanced NPC,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Junshi Biosciences focuses on tumor types that are 1) highly prevalent in China; 2) responsive to immunotherapy; and 3) where there is urgent unmet need for better and safer treatments. The results of POLARIS-02 and JUPITER-02 studies for NPC are representative examples of our clinical program. We are delighted to see that the breakthrough results obtained with toripalimab not only bring new hope to Chinese patients, but also earn international recognition from academia and regulatory authorities. We hope that our novel I-O drug will be available to benefit patients outside China in the near future.”

About Nasopharyngeal Carcinoma
NPC is a primary malignant tumor of the nasopharyngeal mucosal epithelium, which is one of the most common head and neck cancers. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 exceeded 130,000 worldwide, and nearly half of the cases occurred in China. The current therapies are limited for recurrent or metastatic NPC. The first-line standard therapy is platinum-based dual-drug combination chemotherapy. The overall survival of the patients is poor.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells. More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). On December 17, 2018, toripalimab was granted a conditional approval by the National Medical Products Administration (NMPA) for the second-line treatment of unresectable or metastatic melanoma. In December 2020, toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”) after failure of at least two lines of prior systemic therapy. In April, the NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. In November 2021, the NMPA approved toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma. In addition, the supplemental NDA for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma was accepted by the NMPA for review in July 2021.

In the United States, the FDA has granted priority review for the toripalimab BLA for the treatment of recurrent or metastatic NPC, an aggressive head and neck tumor which currently has no FDA-approved immuno-oncology treatment options. Earlier, the FDA granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the 1st line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and orphan drug designation for esophageal cancer, NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021, Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit:

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
+ 86 021-2250 0300

Solebury Trout
Bob Ai
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
+ 86 021-6105 8800

Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors

SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board of Directors of ORIC Pharmaceuticals, Inc., (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

“Jacob is an accomplished life-science executive and highly regarded board member with a track record of building leading oncology-focused biotechnology companies,” said Fredrik Wiklund, President and CEO of Bright Peak. “Jacob will bring scientific insights and a wealth of experience in corporate and financial strategy to Bright Peak during an important time in the company’s continued evolution.”

“We welcome Jacob to the Board and look forward to his many contributions to Bright Peak’s future success,” said Dr. Tom Woiwode, Managing Director of Versant Ventures and Bright Peak Board member. “He is the perfect fit for the company’s next stage of growth, given his substantial biotech company leadership experience.”

“I’m excited to join Bright Peak’s Board of Directors and look forward to working alongside the executive team and my fellow board members to build a leading biotechnology company delivering novel and disease-modifying immunotherapies for patients suffering from cancer and autoimmune disorders,” said Dr. Chacko.

Dr. Chacko has served as CEO of ORIC Pharmaceuticals since April 2018. During Dr. Chacko’s tenure, ORIC has raised over $375mm in private and public financing, including its IPO in April 2020, has advanced its lead program into two Phase 1b trials, has in-licensed two additional programs, and is on track to file three INDs/CTAs in 2021. Prior to ORIC, Dr. Chacko was most recently CFO of Ignyta, a Nasdaq-listed precision oncology company acquired by Roche for $1.9 billion in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company.

Dr. Chacko currently serves on the board of directors of 4D Molecular Therapeutics (Nasdaq: FDMT) and chairs the Western Regional Selection Committee for the Marshall Scholarship. He previously served on the board of directors of Turning Point Therapeutics, Bonti (acquired by Allergan), EnvisionRx (acquired by Rite Aid), RentPath, and the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford; and he was a board observer to Par Pharmaceutical (acquired by Endo), IMS Health and Quintiles Transnational.

Dr. Chacko concurrently received his MD with AOA honors from UCLA and his MBA with Distinction from Harvard Business School. He also received a MSc from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian.

About Bright Peak

Bright Peak is a privately held biotechnology company based in San Diego, USA and Basel, Switzerland dedicated to creating next-generation cytokine immunotherapies for the treatment of patients with cancer and autoimmune disease. Bright Peak is pioneering a novel technology to chemically synthesize enhanced and conjugatable cytokines that exploits the potent biological activity of cytokines while avoiding the severe side effects associated with first-generation therapies. Bright Peak’s enhanced cytokines can be easily conjugated to a diverse array of molecules, such as monoclonal antibodies, creating a novel class of “Bright Peak Immunocytokines”. Bright Peak is funded by a syndicate of leading healthcare investors.


What Thailand can learn about telecom mergers from developed countries

A hot debate has been raging in Thailand since the recent announcement of the plan to merge True Corporation, a subsidiary of conglomerate Charoen Pokphand Group, and Total Access Communication (Dtac), a subsidiary of Norway’s Telenor.

The experience of developed countries with telecom mergers may shed some light on the impacts from the proposed share-swap arrangement between True and Dtac to create a new tech company.

A report, “Static and Dynamic Effects of Mergers: A Review of the Empirical Evidence in the Wireless Telecommunications Industry”, presented at the Global Forum on Competition hosted by the Organisation for Economic Cooperation and Development (OECD) last year, looked at various studies and said the impact on prices for consumers was not clear.

The review looked at 18 empirical studies that assessed the short-term effects on price and long-term effects on investment levels of changes in market concentration in the wireless telecommunications industry. They primarily looked at a scenario of four operators being reduced to three after the merger.

Of the 18 studies, eight analyzed changes in market concentration across multiple jurisdictions between 2000 and 2015, while 10 studies that analyzed specific mergers were divided in their conclusions. About half of the 10 studies that looked at specific mergers found short-term prices decreasing after a merger, while the same number of studies found that short-term prices increased, says the review.

Even different studies of the same merger found wildly different impacts on short-term prices, ranging from significant price decreases to significant price increases. “Thus, looking at these price effects alone, the studies are, collectively, inconclusive,” says the review.

The specific mergers considered in these studies were: T-Mobile/Orange in Netherlands in 2007; Hutchinson/Orange in Austria 2012; Hutchison/Telefonica in Ireland 2014; and Telefonica/KPN in Germany 2014.

Studies of 5-to-4 mergers were T-Mobile/tele.ring Austria in 2006 and T-Mobile/Orange UK in 2010.

Inconclusive but useful studies

The review concluded that: “Four-to-three mergers appear to generate net long-term benefits to consumer welfare in the form of increased investment.”

Despite the lack of definite conclusions on the impact on prices after a merger, the studies have been useful. The value is in the factors that the studies identify or that can be identified from the studies, says the review.

It points out that when taken as a whole, the review reveals a number of factors that should be considered when seeking to understand the likely welfare effects of a given merger.

These include:

¦ whether the effects to be evaluated are limited to static price effects or also include qualitative measures, such as capital expenditures and other investment in the quality of service, suggesting dynamic, innovation effects;

¦ the timeframe over which the effects are evaluated;

¦ the effects on different tiers of service measured by hypothetical consumption profiles or baskets.

Other factors are the presence or entry of mobile virtual network operators; the effects of different geographic circumstances or regulatory regimes on a given firm, and the extent to which the effects of previous mergers may confound projected effects of the merger at hand.

Moreover, attention must be given to whether a transaction occurs during, or even as part of, a transition between different generations of technology such as during an upgrade from 3G to 4G networks, the review says.

Researchers in developed economies have studied 5-to-4 and 4-to-3 merger scenarios, while in Thailand, if the True-Dtac merger goes as planned, the number of mobile operators will reduce from three to two, AIS being the other. Each camp is likely to have half of the market share. Critics worry it will lead to less competition, harming consumer interest.

Stop ‘gun jumping’

Opponents pointed to antitrust benchmarks in advanced economies, which take telecom competition seriously.

Kanoknai Thawonphanit, a lecturer at Thammasat University’s Faculty of Law, urged the regulators to take immediate action in order to prevent the potential merger parties from exchanging trade secrets that could adversely impact market competition.

Kanoknai urged the Trade Competition Commission and telecom watchdog the National Broadcasting and Telecommunications Commission to address the so-called “gun-jumping” practice, which usually happens in the pre-merger period.

According to the OECD, when merging parties fail to notify a merger to the competition authority, implement all or a part of the merger during a mandatory waiting period, or coordinate their competitive behavior before closing, it is commonly called “gun-jumping”.

As an example, Kanoknai said that an exchange of competitively sensitive information is labeled as “gun-jumping” and regulators in the European Union and Germany used to enforce this prohibition rule.

Merger reasons unconvincing

Pornthep Benyaapitkul, an economics lecturer at Thammasat University, said that he did not buy the reasons cited for the merger by True and Dtac executives, which are to increase efficiency and reduce cost.

“If such reasons were stated to European regulators, they would be rejected,” he asserted.

Thanathorn Juangroongruangkit, former leader of the disbanded Future Forward Party, argued that no developed country allows mergers among big players which would shrink the number of players to only two.

Source: Thai Public Broadcasting Service

Thailand’s New COVID-19 Cases Hit Five-Month Low

BANGKOK, Thailand’s COVID-19 cases rose by 4,753, and 27 more fatalities were recorded in the previous 24 hours, the country’s Centre for COVID-19 Situation Administration (CCSA) reported yesterday.

This figure of below 5,000 new caseloads is considered as the lowest since late June.

The CCSA also reported that, all of the new deaths recorded were among senior patients aged over 60 years, and patients with underlying diseases.

In response to the new Omicron variant of the virus, the CCSA confirmed on Saturday that, travellers from eight African nations, including Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, South Africa and Zimbabwe, would not be allowed to enter Thailand from Dec 1 (tomorrow) onwards.

From Nov 1 to Nov 27, 1,007 people arrived in Thailand from southern Africa, and none had tested positive for COVID-19, the CCSA said.

Since the pandemic started early last year, the accumulative number of COVID-19 currently stands at 2,111,566 with a total of 20,734 deaths.

Over 92 million vaccines have been administered nationwide, with roughly 57 percent of the Thai population have been fully vaccinated against the virus so far. Meanwhile, over three million Thais have already received the booster shot.

Source: Nam News Network